Loading blog post…
A complete guide to atopic dermatitis management — the filaggrin-barrier-IgE pathogenesis triad, topical corticosteroid selection and potency ladder, calcineurin inhibitors, dupilumab and emerging biologics, and the proactive maintenance protocol.
· By MedSpot Editorial · 7 min read
Atopic dermatitis (AD) — commonly called eczema — is the most common chronic inflammatory skin disease, affecting 15–20% of children and 2–10% of adults globally. It is not simply dry skin; it is a complex immune-mediated condition driven by barrier dysfunction and type 2 (Th2) immune dysregulation. Here's the complete management framework.
AD pathogenesis involves three interacting components:
1. Barrier dysfunction (filaggrin): Filaggrin loss-of-function mutations are present in ~30% of AD patients — the strongest single genetic risk factor. Filaggrin is essential for forming the cornified cell envelope and generating natural moisturizing factors. Without it, the skin barrier is porous: transepidermal water loss is elevated, pH rises (disrupting enzyme activity), and allergens and irritants penetrate to immune cells in the dermis.
2. Type 2 immune activation: Damaged keratinocytes release thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 → activate innate lymphoid cells type 2 (ILC2) and dendritic cells → Th2 lymphocyte polarization → IL-4, IL-13, IL-31 production. IL-4 and IL-13 drive IgE production and further barrier deterioration. IL-31 is the primary itch mediator — the "itch-scratch cycle" perpetuates barrier damage.
3. Sensitization and triggers: The porous barrier allows percutaneous sensitization to environmental allergens (house dust mite, pet dander, pollen, food proteins). In sensitized individuals, allergen contact triggers IgE-mediated mast cell degranulation → acute flare.
IL-31 → peripheral itch sensory neurons → scratching → physical barrier damage → keratinocyte activation → more TSLP/IL-33 → more Th2 → more IL-31. Breaking this cycle is central to AD management. Even non-lesional atopic skin has elevated TEWL and sub-clinical inflammation compared to non-atopic skin.
AD management has shifted from reactive treatment (only treating flares) to proactive maintenance — treating both active and subclinical disease:
Berth-Jones et al. (2003): Proactive fluticasone propionate 0.05% twice weekly vs. vehicle demonstrated significantly fewer relapses (6.8 vs. 12.8 over 20 weeks). The proactive model is now standard in European and US guidelines.
Moisturization is not optional or adjunctive — it is the primary treatment for mild AD and the foundation of all management levels:
Bathing guidance: Lukewarm (not hot) water; 5–10 minutes maximum; gentle fragrance-free wash; pat dry (not rub); apply emollient within 3 minutes of exiting bath.
TCS are the first-line treatment for active AD flares. Potency selection is the critical skill:
| Class | Potency | Examples | Where to use |
|---|---|---|---|
| VII (lowest) | Mild | Hydrocortisone 0.5–1% | Face, eyelids, skin folds, infants |
| V–VI | Moderate | Triamcinolone 0.025%, desonide 0.05% | Trunk and limbs in children; face short-term |
| III–IV | Mid-high | Triamcinolone 0.1%, mometasone furoate 0.1% | Trunk and limbs in adults; thick lichenified skin |
| I–II (highest) | Very potent | Clobetasol propionate 0.05%, betamethasone dipropionate | Palms, soles; severe lichenified plaques; maximum 2 weeks |
Rules:
Side effects of prolonged inappropriate TCS use: Skin atrophy, striae, telangiectasia, perioral dermatitis, steroid-induced rosacea, HPA axis suppression (rare but possible with potent steroids over large body surface area).
TCIs are steroid-sparing alternatives — no skin atrophy risk, making them preferred for chronic use on the face and skin folds:
Mechanism: Inhibit calcineurin → prevent nuclear factor of activated T cells (NFAT) translocation → block IL-2 and other Th2 cytokine transcription → suppress local T cell activation.
Evidence: Eichenfield et al. (2002, JAAD): tacrolimus 0.1% superior to vehicle for moderate-severe AD at all body sites including face; tacrolimus 0.03% and pimecrolimus 1% both superior to 1% hydrocortisone for facial AD.
Application: To active lesions 2× daily; may be used for proactive maintenance 2×/week on traditionally affected areas. Burning/stinging on application common in first few days and then resolves.
FDA black box warning (2006): Theoretical malignancy risk (based on animal studies at much higher doses); never substantiated in humans in 20+ years of post-marketing. Current evidence does not support avoidance based on malignancy concern. Pediatric approval for pimecrolimus ≥2 years; tacrolimus 0.03% ≥2 years.
Phosphodiesterase 4 (PDE4) inhibitor — 2% ointment; FDA-approved for mild-to-moderate AD ≥2 years. Non-steroidal, non-TCI option. Less potent than tacrolimus but provides an additional non-steroidal option. Stinging on application in ~4% of patients.
Dupilumab is a monoclonal antibody targeting the IL-4Rα receptor — blocking both IL-4 and IL-13 signaling simultaneously. It directly addresses the central Th2 driver of AD.
Simpson et al. (2016, New England Journal of Medicine) — pivotal LIBERTY AD SOLO trials: dupilumab 300 mg SC Q2W vs. placebo in adults with moderate-severe AD → IGA 0/1 (clear/almost clear) in 38% vs. 10% (placebo); EASI-75 (75% improvement) in 44% vs. 12%.
FDA approvals: Adults 2019; children 6–11 years 2022; 6 months–5 years 2023. The broadest biologic approval in AD.
Side effects: Conjunctivitis (most common — 10–28%; manage with ophthalmologist; usually resolves or manageable); injection site reactions; facial redness ("dupilumab head-and-neck dermatitis" — management: low-potency topical steroid or TCI; often resolves over time).
IL-13 specific monoclonal antibody (vs. dupilumab's dual IL-4/13 blockade). FDA-approved for adults with moderate-severe AD 2022. Comparable efficacy to dupilumab with slightly different side effect profile (conjunctivitis rate lower).
IL-13 monoclonal antibody; EU-approved 2023; US approval 2023. ADVOCATE trials demonstrate EASI-75 ~58% at week 16.
JAK inhibitors act faster than biologics (clinical response within 2–4 weeks vs. 8–16 weeks for dupilumab) but carry class effects: infection risk, thromboembolism (boxed warning class), herpes zoster reactivation. Used for patients needing rapid response or biologic failures.
Beyond treatment, identifying and managing triggers reduces flare frequency:
Looking for an eczema or atopic dermatitis consultation? Browse dermatology providers on MedSpot →